In subsequent studies using a CT26 mouse model of colorectal cancer, PVRIG blockade combined with anti-PD-L1 therapy significantly reduced tumor growth (p = 0.0005; 56% tumor growth inhibition) to a higher degree than either agent alone, thus demonstrating the potential value of therapeutically targeting PVRG in addition to other B7 family checkpoints in the setting of malignancy. The gene discussed is PVRIG; the disease is neoplasm.